title: Intravenous infusion of trieicosapentaenoyl-glycerol and LTB4 and LTB5 production by leukocytes of rabbits.
abstract: During myocardial infarction leukotriene B4 (LTB4) is probably a major determining factor of tissue damage because it can amplify the inflammatory reaction by recruiting leukocytes and degranulating them. Oral administration of eicosapentaenoic acid (EPA) is known to reduce LTB4 production by polymorphonuclear leukocytes (PMNL). However, it takes several weeks for EPA to take effect. In this study, we formulated a trieicosapentaenoyl-glycerol emulsion and infused it into rabbits (0.8 g EPA/kg). In the ex vivo study, the inhibition of LTB4 production by PMNL from EPA-infused rabbits was maximal (32-60% of preinfusion values, P less than 0.01) 6 h after the infusion. There was also a tendency toward reduced LTB4 production 1, 24, and 168 h after the infusion. A lower dose (0.2 g EPA/kg) also reduced LTB4 production (45% of preinfusion values, P less than 0.02) 6 h after the infusion. There was no significant change in LTB4 production in control groups in which soybean oil emulsion was infused instead of EPA. EPA infusion might be useful for reduction of tissue damage in the acute phase of LTB4-related diseases such as acute myocardial infarction.
authors.affiliation: First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Sawazaki
authors.forename: N
authors.initials: N
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Hamazaki
authors.forename: K
authors.initials: K
authors.lastname: Yamazaki
authors.forename: M
authors.initials: M
authors.lastname: Urakaze
authors.forename: S
authors.initials: S
authors.lastname: Yano
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000096:biosynthesis / Q000097:blood / Q000494:pharmacology*; D004655:Emulsions; D005990:Glycerol / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007975:Leukotriene B4 / Q000096:biosynthesis* / Q000031:analogs & derivatives; D008055:Lipids / Q000097:blood; D008297:Male; D009504:Neutrophils / Q000378:metabolism*; D009994:Osmolar Concentration; D011817:Rabbits; D013024:Soybean Oil / Q000494:pharmacology; D013997:Time Factors
chemical_list: D004655:Emulsions; D008055:Lipids; D007975:Leukotriene B4; D013024:Soybean Oil; C040212:leukotriene B5; D015118:Eicosapentaenoic Acid; D005990:Glycerol